Pfizer Inc
NYSE: PFE
$24.79
-$1.23 (-4.7%)
Real Time Data Delayed 15 Min.
PFE Articles
The top analyst upgrades, downgrades and initiations seen on Tuesday included Cisco Systems, Duke Energy, Goodyear, Illumina, Kinder Morgan, Micron Technology, Pfizer and Tencent Music.
Published:
Last Updated:
Pfizer and Merck are each scheduled to release their second-quarter financial results early Tuesday. These are just a couple of the Dow Jones industrials that are reporting this week, but they make...
Published:
Last Updated:
Mylan released its second-quarter financial results before the markets opened on Monday. The pharma giant also announced a major update to its business involving Pfizer and that CEO Heather Bresch is...
Published:
Last Updated:
Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week, including Apple, Exxon and Pfizer.
Published:
Last Updated:
The Dow Jones industrial average in an all-time high territory, and a lot of experts believe it has room to run. But one particular stock is not helping.
Published:
Last Updated:
The July 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Intel, Pfizer and Microsoft above all other Dow stocks.
Published:
Last Updated:
The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
Published:
Last Updated:
Here are five solid defensive picks for investors in what is a very expensive market, and they are also under-owned by active fund managers. All are rated Buy at Merrill Lynch.
Published:
Last Updated:
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Published:
Last Updated:
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Published:
Last Updated:
Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in young children with mild to moderate atopic dermatitis, also known as eczema.
Published:
Last Updated:
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
Published:
Last Updated:
The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated: